A股年报披露季开启 沃华医药净利大增162.93%

Group 1 - The core viewpoint of the news is that WoHua Pharmaceutical has reported a significant increase in net profit for 2025, achieving a 162.93% year-on-year growth, marking the highest increase in nearly a decade [1] - In 2025, WoHua Pharmaceutical achieved total operating revenue of 817 million yuan, representing a year-on-year growth of 6.96% [1] - The net cash flow from operating activities increased by 40.45% year-on-year, and the company maintained a healthy asset-liability structure with zero interest-bearing debt [1] Group 2 - The company plans to implement a stable cash dividend scheme, proposing a cash dividend of 1.46 yuan (including tax) per 10 shares for the 2025 interim report [1] - WoHua Pharmaceutical is initiating a strategic optimization and restructuring of its production system in 2025, aiming to enhance operational efficiency and supply chain resilience through resource collaboration and process optimization [1] - Looking ahead to 2026, the company will focus on its core traditional Chinese medicine business, emphasizing the clinical value and market synergy of its exclusive product lines while expanding its outpatient market [2] Group 3 - The company aims to strengthen its research and development and regulatory layout, utilizing refined management practices to improve operational efficiency [2] - The brokerage reports suggest that the traditional Chinese medicine market will continue to grow rapidly, supported by favorable policies and the introduction of new products, driving sustained industry prosperity [2]